biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Jul 21, 2016 12:24pm

67 Views

Post# 25072609

RE:RE:RE:RE:RE:RE:RE:why are we at $1.17 if things are so great ?

Jekyl Jr:

1. Validation requires clinical data
2. Validation requires deal with pharma

Doesn't #2 need to have #1 completed?

Uh huh, now you're back to saying that deals require clinical data, BUT you maintain that we'll have a deal by the end of the month.

Who will be starting and completing a clinical trial in the next 10 days?

You must wake up every morning and say to yourself...

"How can I outdo the stupid stuff I said yesterday???"

Bullboard Posts

Changing Europe’s dependency on HREE from China